Interestingly, loss‐of‐function EZH2 mutations can also promote cancer in a context‐dependent manner (Morin al., 2010; Simon al., 2012) and prolonged inhibition of EZH2 in GBM causes a cell fate switch toward a more undifferentiated and proliferative state, which results in tumor progression(de Vries al., 2015). Here, EZH2 is linked to cancer.